Science & Technology
Science and Technology
Science and Technology
Tue, February 10, 2009 Bio-Matrix Scientific Group?s Stock One of the Top Performers in ETF Innovators Emerging Stem Cell Index
SAN DIEGO--([ BUSINESS WIRE ])--Bio-Matrix Scientific Group, Inc. (OTCBB:BMSN) ([ www.BMSN.us ]), announced today that it is listed among the 29 companies included in the ETF Innovators Expanded Emerging Stem Cell Index, an Index comprised of U.S. listed stocks with market caps below $250 million.
The rise in BMSN's stock price of 11.8 percent, (a 52-week change as of February 5, 2009) represents one of the highest percentage gains in stock price among the companies which comprise this Index. ETF Innovators is an investment weblog with a focus on exchange-traded funds and the healthcare industry.
BMSN, a development-stage biotech company focusing on the cryogenic storage of stem cells and the commercialization of medical devices used in living tissue transfer and stem cell research, was recently the "featured stock of the month" in the KonLin Letter ([ www.KonLin.com ]), a New York-based investment newsletter published by KonLin Research & Analysis Corp.
According to Konrad Kuhn, editor and publisher of The KonLin Letter, "Bio-Matrix Scientific Group, Inc. provides the highest quality stem cell-related processing and cryogenics storage, along with the development of instruments and procedures that assist the medical industry's further expansion into quality of life issues."
About Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN)
Bio-Matrix Scientific Group, Inc., based in San Diego, is a biotech research and development company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market. Bio-Matrix's new 15,000 sq. ft. facility, located in the heart of San Diego's biotechnology corridor, houses the company's two secure Cryogenic Stem Cell Banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing laboratory, hematology, microbiology and flow cytometry laboratories. The company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation.
Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
